catalpol has been researched along with Chronic Illness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Q; Li, H; Yao, Z | 1 |
| Hu, Y; Ke, Z; Wang, Z; Xia, Z; Xiong, Z; Xu, G; Yong, Y | 1 |
2 other study(ies) available for catalpol and Chronic Illness
| Article | Year |
|---|---|
Catalpol promotes oligodendrocyte survival and oligodendrocyte progenitor differentiation via the Akt signaling pathway in rats with chronic cerebral hypoperfusion.
Topics: Animals; Apoptosis; Carotid Artery, Common; Cell Differentiation; Cell Survival; Cerebrovascular Disorders; Chromones; Chronic Disease; Disease Models, Animal; Enzyme Inhibitors; Iridoid Glucosides; Male; Morpholines; Neural Stem Cells; Neuroprotective Agents; Oligodendroglia; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats, Wistar; Signal Transduction | 2014 |
Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cells, Cultured; Chronic Disease; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glial Cell Line-Derived Neurotrophic Factor; Glucosides; Iridoid Glucosides; Iridoids; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Motor Activity; Nerve Degeneration; Neural Pathways; Neurons; Neuroprotective Agents; Probenecid; Substantia Nigra | 2010 |